Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases

Shots:

  • Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including 2 undisclosed Pfizer’s transgenes along with royalties based on sales of products including licensed capsids
  • Pfizer gets the right to assess novel capsids for CNS & cardiac tropisms by utilizing Voyager’s TRACER platform & exercise its options to license capsids for exclusive use in its AAV gene therapies including 2 transgenes
  • Voyager holds global rights for all licensed capsids to use with other transgenes & applications of its TRACER technology

Click here to read full press release/ article | Ref: Voyager Therapeutics | Image: Twitter

The post Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases first appeared on PharmaShots.